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Abstract
Background: Kallmann syndrome (KS), comprised of congenital hypogonadotropic hypogonadism (HH) and
anosmia, is a clinically and genetically heterogeneous disorder. Its exact incidence is currently unknown, and a
mutation in one of the identified KS genes has only been found in ~30% of the patients.
Methods: Herein, we investigated epidemiological, clinical, and genetic features of KS in Finland.
Results: The minimal incidence estimate of KS in Finland was 1:48 000, with clear difference between males (1:30
000) and females (1:125 000) (p = 0.02). The reproductive phenotype of 30 probands (25 men; 5 women) ranged
from severe HH to partial puberty. Comprehensive mutation analysis of all 7 known KS genes (KAL1, FGFR1, FGF8,
PROK2, PROKR2, CHD7, and WDR11) in these 30 well-phenotyped probands revealed mutations in KAL1 (3 men) and
FGFR1 (all 5 women vs. 4/25 men), but not in other genes.
Conclusions: Our results suggest that Finnish KS men harbor mutations in gene(s) yet-to-be discovered with sex-
dependent penetrance of the disease phenotype. In addition, some KS patients without CHD7 mutations display
CHARGE-syndrome associated phenotypic features (e.g. ear or eye anomalies), possibly implying that, in addition to
CHD7, there may be other genes associated with phenotypes ranging from KS to CHARGE.
Introduction
Kallmann syndrome (KS; MIM# 147950), a combination
of congenital hypogonadotropic hypogonadism (HH;
MIM# 146110) and decreased/absent sense of smell,
results from disturbed intrauterine migration of gonado-
tropin-releasing hormone (GnRH) neurons from the
olfactory placode to the hypothalamus [1-3]. Patients
with KS usually lack puberty, but the reproductive phe-
notype may vary from severe hypogonadism (cryptorch-
idism or micropenis in male infants) to reversal of
hypogonadotropism later in life [4,5]. Associated pheno-
typic features include cleft lip/palate, hearing impair-
ment, dental agenesis, limb anomalies, renal agenesis,
and mirror movements [6]. The incidence estimates of
KS are scarce and variable, and the condition appears to
be 3-5 times more frequent in men [6-8].
KS is genetically heterogeneous, and the majority of
cases (~60%) present as sporadic cases (only one person
affected in the family). In familial KS, autosomal reces-
sive, autosomal dominant, and X-chromosomal recessive
inheritance have been described [9]. Oligogenic mode of
inheritance has also been suggested [10-13]. The genes
involved in the etiology of KS are KAL1 [14,15], FGFR1
[16], FGF8 [11], PROK2 [13,17], PROKR2 [13,17], and
WDR11 [18]. A monoallelic mutation in FGFR1 under-
lies approximately 10% of KS cases [16]. Consistent with
variable expressivity of FGFR1 mutations, the mutation
carriers may also display spontaneous fertility
[16,19-21], and loss-of-function mutations in FGFR1 are
found in 7% of patients with congenital HH but report-
edly normal sense of smell [5]. In addition, mutations in
CHD7, underlying over 60% of CHARGE syndrome
(coloboma, heart defects, choanal atresia, retarded
growth and development, genital abnormalities, and ear
anomalies; MIM# 214800) [22,23], have also shown to
cause KS. To date, a molecular genetic diagnosis is
attained in only approximately 30% of KS patients
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Here we provide a nationwide minimal incidence esti-
mate of KS in Finland, describe the phenotypic and
molecular genetic features of a representative series of
Finnish KS patients, and characterize the functional
effects of novel FGFR1 missense mutations.
Materials and methods
Data sources
Discharge registers of all 5 university hospitals in Fin-
land were queried by the International Classification of
Disease (ICD) edition 10 and 9 (ICD-10, -9) codes for
hypogonadotropic hypogonadism (E23.04 and 253.4,
respectively) covering the years from 1996 to 2007.
Among the query results, in any case of hypogonadotro-
pic hypogonadism, the medical charts were manually
revised, and all patients of Finnish origin who had been
diagnosed with KS on the basis of isolated gonadotropin
deficiency without an organic cause, and anosmia or
hyposmia, were identified. Of note, anosmia or hypos-
mia had been diagnosed on the basis of anamnestic
information, olfactometry, or by the inability to recog-
nize familiar odors such as coffee. All except one
(excluded from further calculations), were born between
1976 and 1987. Thus the final series of hereby identified
KS patients reflects the number of KS patients born in
Finland between 1976 and 1987. To estimate a national
incidence of KS, this number of KS patients was com-
pared to the number of live-born children in Finland
between 1976 and 1987 (Statistics Finland register data-
base at http://pxweb2.stat.fi/database/StatFin/vrm/synt/
synt_en.asp).
Clinical and molecular genetic evaluation of the patients
Medical history and clinical examination
The patients willing to participate in the molecular
genetic part of this study were enrolled from the 5 dif-
ferent university hospitals in Finland, and were asked
for a detailed medical history including history of cryp-
torchidism, micropenis, prior pubertal development,
prior treatment, associated phenotypes, and the sense of
smell, and these data were verified by medical chart
review. Patients were also asked for the presence or
absence of KS, normosmic HH, infertility, isolated anos-
mia or hyposmia, cryptorchidism, delayed puberty, den-
tal agenesis, or cleft lip and palate in their family
members and relatives. In retrospect, all adult patients
fulfilled the following criteria: 1) absent or incomplete
pubertal development by the age of 18 yrs, 2) low circu-
lating basal sex steroid levels in association with inap-
propriately low or normal gonadotropin levels, and
subnormal or normal response to GnRH stimulation
test, 3) otherwise normal anterior pituitary function, 4)
anosmia or hyposmia based on either anamnestic infor-
mation, formal testing (e.g. olfactometry), or testing with
familiar odors, and 5) no organic cause for their condi-
tion. In addition to adult patients, 12-18 yr-old-patients
with unequivocal signs of severe congenital HH (history
of cryptorchisim and/or micropenis), absent puberty,
and anosmia/hyposmia were enrolled.
The participants underwent a complete physical exam-
ination, including mirror movement assessment, and
measurement of testicular volume with a ruler (length ×
width
2 × 0.52). Olfaction was assessed with the 40-item
smell testing (University of Pennsylvania Smell Identifi-
cation Test, UPSIT, Sensonics Inc, Haddon Heights,
NJ), and individuals scoring <5
th percentile for age in
UPSIT, were classified as anosmic. A blood sample was
drawn for DNA extraction. Renal structures were
assessed by abdominal ultrasound scan. The following
brain magnetic resonance imaging (MRI) protocol was
used to visualize the olfactory bulbs, sulci, and inner
ears (corresponding sequences in 1.5 and 3 tesla units):
axial T2 FSE and FLAIR images of the whole brain, cor-
onal T2 FSE with 3 mm slice thickness starting from
the anterior surface of the frontal lobe, 3D MPR sagittal
images (1 × 1 mm) covering the whole head with coro-
nal reconstructions, 3D T2-weighted thin slices (CISS,
DRIVE, voxel size 0.3-0.5 mm × 3) axial images from
the region of the inner ear. No contrast medium was
used.
The family members willing to participate were con-
tacted and recruited with the permission of the proband,
and they filled in a questionnaire or were interviewed by
telephone for prior pubertal development, fertility, asso-
ciated phenotypes, and the sense of smell. A blood sam-
ple was drawn for DNA extraction.
Mutation analysis
Genomic DNA from peripheral blood leukocytes was
extracted, and the coding exons and exon-intron bound-
a r i e so f8g e n e s[ KAL1 (MIM# 308700; RefSeq
NM_000216.2, gi:119395745), FGFR1(MIM# 136350;
RefSeq NM_023110.2, gi:105990521), FGF8 (MIM#
600483; RefSeq NM_033163.3, gi:298919216), PROK2
(MIM# 607002; RefSeq NM_001126128.1, gi:187167260),
PROKR2 (MIM# 607123; RefSeq NM_144773.2,
gi:30581162), NELF (MIM# 608137; RefSeq
NM_001130969.1, gi:195972908) [26], CHD7 (MIM#
608892; RefSeq NM_017780.2, gi:54112402) and WDR11
(MIM# 606417; RefSeq NM_018117.11, gi:284172506)]
were PCR-amplified and screened by direct sequencing.
In FGFR1, both exons 8A and 8B, generating isoforms
FGFR1-IIIb and FGFR1-IIIc by alternative splicing [27],
respectively, were screened. FGFR1 and CHD7 were also
analyzed by multiplex ligation-dependent probe amplifi-
cation assay (MLPA). MLPA was performed according to
manufacturer’sp r o t o c o l( S a l s aM L P AK i t sP 1 3 3
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Amsterdam, the Netherlands). All primer sequences and
PCR conditions are available upon request. Nonsense
changes resulting in a truncated protein, nucleotide
changes affecting splice sites, and frameshifting insertions
or deletions were categorized as pathogenic mutations.
Missense changes, which were absent from the Single
Nucleotide Polymorphism database (http://www.ncbi.nlm.
nih.gov/projects/SNP/) and from at least 100 controls
from the same geographical region, were identified as pos-
sibly pathogenic mutations, and characterized further by
functional in vitro studies. Mutationsw e r ec o n f i r m e d
from a second PCR product. Mutation nomenclature is
according to the guidelines of the Human Genome Varia-
tion Society [28] and was verified using the Mutalyzer soft-
ware (http://www.mutalyzer.nl/2.0/).
This study was performed with appropriate permis-
sions from the Ethics Committee (E7) of the Helsinki
University Central Hospital, and from each university
hospital in Finland. Written informed consents were
obtained from the participants, and also from their guar-
dian if the participant was less than 16 yrs of age.
Site-directed mutagenesis
N-terminal myc-tagged FGFR1c cDNA in pcDNA3.1+
was used as a template for site-directed mutagenesis
using QuikChange II XL site-directed mutagenesis kit
(Stratagene, La Jolla, CA). Following mutagenesis, the
sequence of the whole plasmid, including the presence
of the mutation (G48S, R209H, or E670A), was verified.
The myc-tagged FGFR1c cDNA was used for all in vitro
studies, as described [5].
Transfections
All transfections were performed with 300 ng of DNA
(50 ng of myc-tagged WT or mutated FGFR1 cDNA
and 250 ng of empty vector (EV)) in 24-well plates,
using FuGene HD transfection reagent (Roche Diagnos-
tics GmbH, Mannheim, Germany) according to the
manufacturer’s instructions.
Receptor expression and maturation studies
For endoglycosidase digestions, sub-confluent COS-1
cells were transiently transfected. 24 h later, cells were
washed with phosphate buffered saline (PBS) and lysed
with 100 μl of radioimmunoprecipitation assay buffer
(Sigma, Saint Louis, MO) containing 1X Halt protease
inhibitor cocktail (Pierce, Rockford, IL). For deglycosyla-
tion analysis, 5 μg of protein (Protein Quantification kit-
Rapid (Sigma-Aldrich Chemie GmbH, Buchs, Switzer-
land)) was subjected to PNGasef and EndoHf digestion
according to manufacturer’s recommendations (New
England Biolabs, Ipswich, MA).
Western blot analysis
Both untreated or endoglycosidase-treated samples were
resolved on PAGEr Gold Precast 4-20% Tris-Glycine
Gels (Lonza, Rockland, ME), and subjected to western
blot analysis using an anti-myc antibody (1:1000, clone
4A6, Millipore, Billerica, MA). Immunoreactivity was
visualized using Amersham ECL Western blotting detec-
tion reagents (GE Healthcare Limited, Buckinghamshire,
UK). To control for equal loading, blots were stripped
(Restore Western Blot Stripping Buffer (Pierce, Rock-
ford, IL)), and reprobed using anti-b-actin primary anti-
body (1:1000, Santa Cruz Biotechnology, Santa Cruz,
CA). Overall expression levels were visualized from the
PNGase-treated samples, and receptor maturation pat-
terns from the EndoHf-treated samples. Endoglycosidase
experiments were repeated at least three times.
Cell-surface expression
Cell-surface expression was determined with ELISA
technique. Sub-confluent COS-1 cells were transiently
transfected, and, 24 h later, washed with PBS, fixed with
4% paraformaldehyde in PBS for 15 min, and blocked
with PBS, containing 1% bovine serum albumin, for 1 h.
Cell-surface expression levels were determined using an
anti-myc primary-antibody (see above), HRP-conjugated
secondary antibody and assayed using 3,3`,5,5`tetra-
methylbenzidine (Sigma, Saint Louis, MO) as the sub-
strate with detection at 450 nm following the addition
of 0.5 M H2SO4 [29]. Experiments were performed in
triplicate and repeated at least three times.
MAPK signaling studies
L6 myoblasts were transiently transfected at 10% con-
fluency. 5 h later, culture medium was replaced with
starvation media (2% fetal bovine serum). 20 h later, the
cells were stimulated with FGF2 (Cell Signaling Tech-
nology, Danvers, MA), 50 ng/ml for 0/2/10/30 min. At
the indicated time points, the cells were washed with
ice-cold PBS and lysed with 50 μl of radioimmunopreci-
pitation assay buffer (Sigma, Saint Louis, MO), contain-
ing 1X Halt phosphatase inhibitor cocktail (Pierce,
Rockford, IL), and lysates of 3 replicate wells at each
time point were pooled for western blot analyses. Sam-
ples containing equal amounts of protein (8 μg) were
resolved as described above, and subjected to western
blot analysis using a phospho-p44/42 MAPK (Thr202/
204) antibody (1:1000, Cell Signaling Technology, Dan-
vers, MA). Immunoreactivity was visualized as described
above. To control for equal loading, blots were reprobed
using a p44/42 MAPK primary antibody (1:1000, Cell
Signaling Technology, Danvers, MA). Experiments were
repeated at least three times.
Statistical analyses
Fisher’s exact test was used to determine statistical sig-
nificance (Simple Interactive Statistical Analysis, SISA,
http://www.quantitativeskills.com/sisa/). All p-values are
two-sided, and p < 0.05 was considered significant.
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Minimal estimate of the incidence of KS in Finland
Based on the hospital databases, between 1996 and 2007,
altogether 16 KS patients (13 boys and 3 girls) of Finnish
origin had been diagnosed in the 5 university Hospitals
in Finland. They were born between 1976 and 1987,
when altogether 767 778 infants were born alive in Fin-
land. Thus, the minimal estimate of the overall incidence
of KS was 16/767 778 (1 in 48 000 newborns). There was
a clear difference in estimates between boys (13/392 900;
1 in 30 000) and girls (3/374 878; 1 in 125 000) (p = 0.02).
Molecular genetic and clinical features of KS patients
Thirty probands (25 men and 5 women) participated in
the molecular genetic part of our study (mean age 37
yrs, range 13-61 yrs). Two of the men were of other
than Finnish origin. Of note, the male-to-female ratio
among these participants was not different from that of
the patients diagnosed bet w e e n1 9 9 6a n d2 0 0 7( s e e
above). Fifteen of the 30 probands (50%) had at least
one relative with cleft lip and/or palate, isolated anos-
mia, normosmic HH, or KS. All Finnish KS subjects dis-
played unequivocal anosmia as tested with the 40-item
UPSIT test. Overall, 12 of 30 (40%) probands carried a
mutation in either FGFR1 (9 probands) or KAL1 (3 pro-
b a n d s )( T a b l e1 ) .N om u t a t i o n sw e r ed e t e c t e di n
PROK2, PROKR2, FGF8 or WDR11. Importantly, all 5
women had FGFR1 mutations, in contrast to only 4 of
25 men (Table 1) (p = 0.0009). This difference in the
prevalence of FGFR1 mutation carriers among men and
women affected by KS persisted statistically significant
when analyses included only probands of Finnish origin
(5 women, 3/23 men) (p = 0.0006), or those of Finnish
origin without a KAL1 mutation (5 women, 3/20 men)
(p = 0.001). No intragenic aberrations were found in
MLPA analysis of FGFR1; all the FGFR1 mutations were
detected by standard sequencing.
Variable expressivity of FGFR1 mutations was noticed
within families (Figure 1). The proband #11 with a pre-
viously reported FGFR1 missense mutation (c.142G > A
[p.G48S]) [20], had a severe congenital HH (see Table
1). However, her anosmic father carrying the same
mutation had had four children during testosterone
therapy, consistent with active spermatogenesis, and her
brother had normosmic HH. Also, the associated pheno-
types among FGFR1 mutation carriers varied. The pro-
band #20, and his brother with normosmic HH, had the
same missense mutation (c.2009A > C [p.E670A]); the
brother also had cleft lip and palate, and limb malfor-
mations manifested as a fusion of 3
rd and 4
th metatarsal
bones, and missing of the 2
nd and 3
rd toe in both feet
(see Table 1). In addition, proband #503 with a frame-
shift mutation (c.1305_1306dupAT [p.S436YfsX3]) had
two children following assisted reproductive techniques,
Table 1 Clinical and molecular genetic features of the probands with Kallmann Syndrome
Mutation History of Olfaction
Proband Sex Family
history
Gene Nucleotide
change
Predicted
effect
Micro-
penis
Cryptor-
chidism
Puberty SIT MRI of OB Associated phenotypes in
physical examination
1F N o FGFR1 c.246_247delAG* p.
E84GfsX26
No
# A Absent A missing tooth
11 F KS, nHH FGFR1 c.142G > A p.G48S No A NA None
45 F Infertility FGFR1 c.961_962delAA p.
K321RfsX13
No A Absent l.dx,
small l.sin
None
503 F KS FGFR1 c.1305_1306dupAT p.S436YfsX3 No A Absent None
54 F KS FGFR1 c.1825C > T p.R609X No A Absent Cleft lip, two missing teeth,
scoliosis
13 M No FGFR1 c.626G > A p.R209H Yes No No A NA None
14 M KS FGFR1 c.961_962delAA p.
K321RfsX13
NA No Partial
§ A Rudimentary None
20 M nHH
¤ FGFR1 c.2009A > C p.E670A Yes No No A NA Cleft lip and palate
50 M KS, nHH FGFR1 c.11G > A p.W4X NA No No NA NA None
2M K S KAL1 g.2357_2360delAgta Yes Bilat No A NA Synkinesia, a missing tooth
4M K S KAL1 c.784C > T p.R262X Yes Bilat No A NA Synkinesia, left renal
agenesis, rheumatoid
arthritis
9M K S KAL1 c.471_472delCT p.
S158WfsX45
NA R No A NA Synkinesia, unilateral
conductive hearing loss
*de novo -mutation;
#Testicular volume less than 4 mL in males or no spontaneous thelarche in females;
§Testicular volume 6 mL at the age of 33;
¤A brother
with normosmic HH, cleft lip and palate, and limb anomalies.
SIT, The Smell Identification Test; OB, olfactory bulbs; F, female; M, male; nHH, normosmic HH; R, right; A, anosmia; NA, not assessed.
FGFR1 MIM# 136350; RefSeq NM_023110.2, gi:105990521.
KAL1 MIM# 308700; RefSeq NM_000216.2, gi:119395745.
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proven carrier of de novo FGFR1 mutation. The parents
of probands #13, #14, #20, #50, #54, and #503 were una-
vailable for the mutation analysis.
Three probands had mutations in KAL1 (Table 1). In
two pedigrees, the X-chromosomal recessive mode of
inheritance was apparent (Figure 1). The sister of the
proband #2, and the mother and the sister of the pro-
band #9 were all unaffected heterozygous carriers of a
KAL1 mutation.
O n ep r o b a n dc a r r i e dan o v e lm i s s e n s ec h a n g ei n
CHD7 (c.7988C > T [p.A2663V), not present in 100
controls. This variant was predicted to be benign by
PolyPhen [30] (http://genetics.bwh.harvard.edu/pph/),
and it is therefore unlikely that this is a disease-causing
mutation. CHD7 was also analyzed by MLPA because
intragenic CHD7 d e l e t i o n sh a v eb e e nf o u n di nu pt o
22% of CHARGE patients [31,32], but none were
detected in our KS patients.
In addition, novel missense changes in NELF (c.280 G
> A [p.G94S], c.1514 C > T [p.T505M]) were found in
probands carrying an FGFR1 mutation (proband #13:
G94S, proband #54: T505M). However, these were also
present in the controls (G94S: 6/100, T505M: 1/100).
Functional characterization of mutant FGFR1s
To examine the functional consequences of the FGFR1
missense mutations G48S, R209H, and E670A, we com-
pared total and cell-surface expression, receptor matura-
tion, and signaling activities of WT and mutant
receptors.
Overall expression and receptor maturation
Western blot analysis showed two immunoreactive spe-
cific bands for wild-type (WT) FGFR1 at approximately
140 kDa and 120 kDa (Figure 2A). Removal of all types
of N-linked carbohydrate chains with PNGase digestion
reduced the bands into a single one of ~100 kDa. The
overall expression of the mutant FGFR1s G48S, R209H,
and E670A, as judged from the PNGase-treated samples,
was not significantly decreased, as compared to WT
(Figure 2A, upper panel). Endoglycosidase H (EndoHf)
treatment, which removes only high-mannose N-linked
#11 #45 #503 #54
#14 #20 #50
#2 #4 #9
FGFR1:
c.142G>A
(p.G48S)
FGFR1:
c.142G>A
(p.G48S)
FGFR1:
n/n
FGFR1:
c.1305_1306dupAT
(p.S463YfsX3)
4 3
FGFR1:
c.1825C>T
(p.R609X)
FGFR1:
c.962_963delAA
(p.K321RfsX13)
2
FGFR1:
c.2009A>C
(p.E670A)
FGFR1:
c.2009A>C
(p.E670A)
KAL1:
c.784C>T
(p.R262X)
4
KAL1:
c.471_472delCT
(p.S158WfsX45)
KAL1:
c.471_472delCT
(p.S158WfsX45)
KAL1:
c.471_472delCT
(p.S158WfsX45)
FGFR1:
c.962_963delAA
(p.K321RfsX13)
FGFR1:
c.962_963delAA
(p.K321RfsX13)
IHH
Anosmia/
Hyposmia
Cleft
lip/palate
Limb
phenotype
Unaffected
carrier
KAL1:
g.2357_2360
delAgta
KAL1:
g.2357_2360
delAgta
n n
FGFR1:
c.11G>A
(p.W4X)
n
n n n
Figure 1 Pedigrees of KS patients carrying an FGFR1 or KAL1 mutation. Pedigrees #11, #503, #45, #54, and #50 are consistent with
autosomal dominant form of inheritance. X-chromosomal recessive inheritance is apparent in pedigrees #2 and #9.
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Figure 2 Functional analyses of FGFR1 mutants. A. Endoglycosidase analysis of mutant FGFR1s. COS-1 cells were transiently transfected with
myc-tagged WT or mutated FGFR1 cDNA. EV= empty vector. Cell lysates were subjected to PNGase (PNG, upper panel) or EndoHf (EH, lower
panel) digestion. The overall expression of the G48S, R209H and E670A was not significantly decreased as compared to WT (PNGase-treated
bands). Receptor maturation patterns are shown in lower panel. The G48S, R209H and E670A mutants have a similar maturation pattern as WT
receptor. B. Cell-surface expression of FGFR1 mutants. COS-1 cells were transiently transfected with myc-tagged WT or mutated FGFR1 cDNA. EV
= empty vector. Cell-surface expression levels were determined from fixed cells using an anti-myc primary antibody. Absorbancies were detected
at 450 nm. The values on the Y-axis represent fold inductions as compared to the level elicited by EV. The WT, G48S, R209H and E670A have
similar cell-surface expression levels. C. MAPK signaling analysis of FGFR1 mutants. L6 myoblasts were transiently transfected with myc-tagged
WT or mutated FGFR1 cDNA and treated with FGF2 for 0/2/10/30 min. Phospho-specific antibodies (phospho-p44/42 MAPK) were used to
determine phosphorylation of MAPK. To control for equal loading, blots were reprobed using an anti p44/42 MAPK antibody. WT and R209H
show clear phosphorylation of MAPK after 10 and 30 minutes of FGF2 treatment. With the mutant receptors G48S and E670A, no clear
phosphorylation of MAPK was seen in any of the indicated time points. For comparison of baseline activities, all untreated samples (0 min) were
also run on the same gel.
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resulted in similar maturation patterns for G48S,
R209H, and E670A, as compared to WT, as only the
minor 120 kDa bands changed mobility (Figure 2A,
lower panel). This indicates that this minor band repre-
sents the partially processed receptor, whereas the 140
kDa EndoHf resistant band represents the fully glycosy-
lated, mature form of FGFR1.
Cell-surface expression
Cell-surface expression of the WT receptor and the
mutants G48S, R209H, and E670A were examined in
COS-1 cells. Consistent with the results of deglycosyla-
tion experiments, the G48S, R209H, and E670A mutants
had similar cell-surface expression levels as WT (Figure
2B).
MAPK signaling
The signaling activities of the FGFR1 mutants G48S,
R209H and E670A were assayed in L6 myoblasts, a cell
line largely devoid of endogenous FGFRs and FGFs [33].
Cells were transfected with WT or mutant FGFR1s, and
treated with FGF2 for 0/2/10/30 min. Cells expressing
WT receptor showed clear phosphorylation of MAPK
after 10 and 30 min of FGF2 treatment (Figure 2C). No
ligand-induced phosphorylation of MAPK was seen in
cells transfected with G48S and E670A, whereas the
R209H responded to FGF2 treatment similarly to WT
(Figure 2C). All untreated samples were also run on the
same gel, and did not display differences in MAPK
phosphorylation, indicating similar baseline activities
(Figure 2C).
Features of KS patients without KAL1 or FGFR1 mutations
All 18 probands without an identified molecular genetic
cause underlying KS were men. A subset of 7 probands
had a history of micropenis, and 4 of them also dis-
played cryptorchidism, consistent with deficient
hypothalamic-pituitary-gonadal (HPG) axis activation in
fetal life and/or during infancy. Pubertal development
was absent in 15 probands, whereas 3 men had dis-
played partial puberty. In addition, three probands had
CHARGE syndrome-associated features. One of them
had hypoplastic lateral and superior left semicircular
canals, as well as absent right posterior canal (Figure 3).
His child had unilateral microphthalmia and bilateral
coloboma. The second proband displayed cleft lip and
palate, unilateral microphthalmia and coloboma, bilat-
eral hearing impairment, left facial nerve palsy, cup-
shaped ears, upper body muscular atrophy, and hypo-
plastic semicircular canals. Thus, he fulfilled the diag-
nostic criteria for CHARGE syndrome [34]. The third
proband also had cup-shaped ears and upper body mus-
cular atrophy; unfortunately, MRI scan was not avail-
able. However, none of these 3 probands had mutations
in CHD7.
Discussion
Our results show that the nationwide minimal incidence
of KS was approximately 1 in 48 000 in Finland. The
incidence in men (1 in 30 000) was considerably lower
than reported among male military conscripts in France
(1 in 10 000) [35], and higher than in Sardinia (1 in 84
000) [36]. Military conscript screening, however, may
not be the optimal method to ascertain the incidence of
KS because the sense of smell is not typically asked for,
and patients with mild reproductive phenotype may
escape detection. On one hand, our retrospective study
approach - to identify all diagnosed KS cases throughout
Finland born during a defined time period - does not
account for those who remain undiagnosed with KS due
to partial pubertal development or unrecognized hypos-
mia. On the other hand, the proportion of patients with
milder reproductive phenotype is relatively small,
because, in Finland, the onset and progression of pub-
erty both in boys and in girls is verified by a general
practitioner at school welfare clinics, and those without
signs of puberty at an appropriate age are referred to a
pediatrician or pediatric endocrinologist. The observed
sex difference in our minimal incidence estimate of KS
was unlikely due to referral bias. This four-fold inci-
dence in men as compared to women was consistent
with the estimates for single tertiary referral centers
[6,8]. The exact reason for this male predominance is
currently unknown. Possible explanations include under-
diagnosis in female teenagers, or sex-dependent pene-
trance of the mutations in unknown KS genes due to
either differences in embryonic development or in sus-
ceptibility of the HPG axis to disturbances in boys.
In addition to sex-specific difference in the incidence
of KS, the molecular genetic diagnoses also differed
between sexes. Although FGFR1 mutations are not the
sole cause of KS in women worldwide [11,22,23,37], all
5 female probands herein carried an FGFR1 mutation, a
proportion significantly higher than in men. A similar
sex-specific difference between FGFR1 mutation carriers
was also observed among a large series of normosmic
HH patients [5]. From the clinical point of view, KS was
passed on to offspring via assisted reproductive techni-
ques in two families, suggesting that all patients with
A
*
B C
Figure 3 The axial 3D T2-weighted MRI images from the
region of the inner ear of (A) a KS patient with normal
semicircular canals (asterisk), and (B) a KS patient with
hypoplastic semicircular canals (arrow), and an unspecified
atrophic area (arrow head) in his retina (C).
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be offered genetic counseling, similarly as in other situa-
tions in which an inherited condition in the family is
suspected or detected [38].
All nine identified FGFR1 mutations are located in dif-
ferent domains of the receptor (Figure 4), and four of
them were novel (W4X, R209H, E670A, and
S436YfsX3). The nonsense mutations W4X, and R609X
[39], and the frameshift mutations E84GfsX26 [40],
K321RfsX13 [40], and S436YfsX3, all lead to premature
stop codons. Both missense mutations G48S [20] and
E670A, found in patients with familial KS, displayed
impaired downstream signaling as assessed by MAPK
phosphorylation. G48S is located in the first immuno-
globulin-like domain, which is involved in the receptor
autoinhibition, and interacts with the second and the
third immunoglobulin -like domains. These interactions
alter the affinity for ligand and heparin [41,42]. E670A,
located in the intracellular tyrosine kinase domain of the
receptor, is anticipated to disrupt autophosphorylation
of the TK domain [42]. These results were consistent
with loss-of-function. On the other hand, R209H dis-
played relatively normal MAPK signaling, which sug-
gests that another signaling pathway may be impaired
by this mutation.
Overall, 40% of the probands, a proportion similar to
that observed in other populations [20], could be given
a molecular genetic diagnosis. In our series, three (12%)
men had KAL1 mutations which all are expected to
cause loss-of-function of anosmin-1: both the nonsense
mutation R262X [43], and the frameshift mutation
S158WfsX45, lead to premature stop codons in the
region encoding the first fibronectin type III-like repeat
of the protein [44], and the deletion of the last nucleo-
tide of exon 8 and the first three nucleotides of intron 8
(g.2357_2360delAgta) abolishes the splice site, and most
likely results in an incorrect transcript. All probands
with a KAL1 mutation had severe congenital HH in
combination with synkinesia, and the proband with the
R262X mutation also had renal agenesis.
CHD7 mutation analysis has been suggested for KS
patients with CHARGE syndrome-like features [23].
However, patients with KS or normosmic HH without
suggestive features may also carry CHD7 mutations
[ 2 2 , 4 5 ] ,a n de v e nh a v ec h i l d r e nw i t hC H A R G Es y n -
drome [45]. Thus, CHD7 mutation analysis should be
considered for all KS patients. None of our three pro-
bands with CHARGE syndrome-like features carried
mutations in CHD7, analyzed both by direct sequencing
and MLPA, expanding the phenotypic overlap between
KS and CHARGE also in patients without CHD7
mutations.
In rare occasions, a congenital HH patient may carry
mutation(s) in more than one HH gene; Falardeau et al.
[11] showed that mutations in FGFR1 and FGF8 syner-
gized to cause severe congenital HH in a male patient.
Also, mutations in NELF have been suggested to modify
KS phenotype [10,12], but evidence of its involvement
in congenital HH is not thoroughly convincing. In the
current work, none of the patients carried presumably
pathogenic mutations in more than one gene (FGFR1 or
KAL1). However, two probands with an FGFR1 defect
did also harbor novel variants in NELF (G94S and
T505M), but given that the incidence of KS in Finland
was 1 in 48 000 and these variants were also present in
6% and 1% of the controls, it is apparent that these var-
iants are not causing congenital HH. Of note, lack of
mutations in PROK2 and PROKR2, now known to cause
autosomal recessive KS [13,17,37,46], probably reflects
the unique genetic heritage of the Finnish population
[47].
To the best of our knowledge, this is the first study
where WDR11 h a sb e e na n a l y z e di nas e r i e so fK S
patients after Kim et al. identified this gene by posi-
tional cloning of a translocation breakpoint in a KS
patient, and discovered heterozygous missense variants
in this gene in 6/201 (3%) of patients with KS or nor-
mosmic HH [18]. However, we did not detect any muta-
tions, supporting the fact that mutations in WDR11 are
rarely involved in congenital HH, at least in the Finnish
population.
In contrast to women, the majority of male probands
remained without identified mutations, implying the
existence of still undescribed gene(s) underlying KS in
Finnish men. Indeed, sex-dependent penetrance of the
mutations in KS genes yet-to-be discovered could con-
tribute to the higher incidence of KS in men worldwide.
Conclusions
K Si sar a r ec o n d i t i o nw i t han a t i o n w i d em i n i m a li n c i -
dence estimate of 1:48000 in Finland. In Finnish men,
mutations were detected in only KAL1 and FGFR1,a n d
1 822 S
P D1
A
B D2 D3
T
M TK1 TK2
G48S R209H E670A
E84GfsX26 K321RfsX13 S436YfsX3
JM
W4X R609X
Figure 4 Schematic of the FGFR1 mutations at protein level. SP,
signal peptide; D1-D3, immunoglobulin-like domains; TM,
transmembrane domain; JM, juxtamembrane domain; TK1-2, tyrosine
kinase domain (contains two subdomains). The G48S mutation is
located in the first immunoglobulin-like domain (D1), involved in
the receptor autoinhibition. The R209H mutation is located in D2,
responsible for ligand binding and specificity. The E670A mutation
lies within TK2, responsible for activating the MAP (mitogen-
activated protein) kinase pathway. The nonsense mutations, W4X
and R609X, and the frameshift mutations (E84GfsX26, K321RfsX13,
S436YfsX3), all lead to premature stop codons.
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Page 8 of 10all women had loss-of-function mutations in FGFR1.
Some KS patients without CHD7 mutations display
CHARGE syndrome-associated phenotypic features,
implying that, in addition to CHD7,t h e r em a yb eo t h e r
genes associated with both syndromes.
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